☰

Edward Rosfjord, PhD - Publications

Affiliations: 
2000- Oncology Pfizer Research Pearl River 
Tree Info Similar researchers PubMed Report error

34 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Graziani EI, Sung M, Ma D, Narayanan B, Marquette K, Puthenveetil S, Tumey LN, Bikker J, Casavant J, Bennett EM, Charati MB, Golas J, Hosselet C, Rohde CM, Hu G, ... ... Rosfjord E, et al. . Molecular Cancer Therapeutics. PMID 32747418 DOI: 10.1158/1535-7163.Mct-20-0237  0.346
2020 Betts A, Clark T, Jasper P, Tolsma J, van der Graaf PH, Graziani EI, Rosfjord E, Sung M, Ma D, Barletta F. Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1. Journal of Pharmacokinetics and Pharmacodynamics. PMID 32710210 DOI: 10.1007/S10928-020-09702-3  0.319
2020 Mathur D, Root AR, Bugaj-Gaweda B, Bisulco S, Tan X, Fang W, Kearney JC, Lucas J, Guffroy M, Golas J, Rohde CM, Stevens C, Kamperschroer C, Kelleher K, Lawrence-Henderson RF, ... ... Rosfjord E, et al. A Novel GUCY2C-CD3 T cell Engaging Bispecific construct (PF-07062119) for the Treatment of Gastrointestinal Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31996389 DOI: 10.1158/1078-0432.Ccr-19-3275  0.37
2020 Zhong W, Myers JS, Wang F, Wang K, Lucas J, Rosfjord E, Lucas J, Hooper AT, Yang S, Lemon LA, Guffroy M, May C, Bienkowska JR, Rejto PA. Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors. Bmc Genomics. 21: 2. PMID 31898484 DOI: 10.1186/S12864-019-6344-3  0.381
2020 Mathur D, Root A, Bugaj-Gaweda B, Tan X, Fang W, Bisulco S, Golas J, Fernandez D, Kearney J, Upeslacis E, Yao J, Rosfjord E, Stevens C, Kobylarz K, King L, et al. Abstract 2283: A novel GUCY2C - CD3 bispecific engages T cells to induce cytotoxicity in gastrointestinal tumors Immunology. DOI: 10.1158/2326-6074.Tumimm19-A16  0.339
2020 Yao J, Mathur D, Yang S, Conant R, Kearney J, Buklan V, Golas J, Rosfjord E. Abstract 4549: Evaluation of GUCY2c-CD3 bispecific targeting GI cancers in an orthotopic colorectal tumor model Immunology. 80: 4549-4549. DOI: 10.1158/1538-7445.Am2020-4549  0.386
2019 Arensman MD, Yang XS, Leahy DM, Toral-Barza L, Mileski M, Rosfjord EC, Wang F, Deng S, Myers JS, Abraham RT, Eng CH. Cystine-glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America. PMID 31019077 DOI: 10.1073/Pnas.1814932116  0.306
2018 Sung MS, Hopf C, Upeslacis E, Golas J, Kaplan M, Khandke K, Charati M, Kotch F, Loganzo F, Geles K, Lucas J, Gerber H, Sapra P, Rosfjord E. Abstract 818: NG-HER2 ADC (PF-06804103) is superior to trastuzumab emtansine in a mouse 'avatar' head-to-head clinical trial Cancer Research. 78: 818-818. DOI: 10.1158/1538-7445.Am2018-818  0.404
2017 Sung M, Tan X, Lu B, Golas J, Hosselet C, Wang F, Tylaska L, King L, Zhou D, Dushin R, Myers JS, Rosfjord E, Lucas J, Gerber HP, Loganzo F. Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1). Molecular Cancer Therapeutics. PMID 29054985 DOI: 10.1158/1535-7163.Mct-17-0403  0.331
2017 Damelin M, Bankovich A, Bernstein J, Lucas J, Chen L, Williams S, Park A, Aguilar J, Ernstoff E, Charati M, Dushin R, Aujay M, Lee C, Ramoth H, Milton M, ... ... Rosfjord E, et al. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Science Translational Medicine. 9. PMID 28077676 DOI: 10.1126/Scitranslmed.Aag2611  0.395
2017 Cao J, Zhu Z, Wang H, Nichols T, Rosfjord E, Hopf C, Upeslacis E, Rejto P, Weinrich S, Vanarsdale T, Hardwick J, Wei P. Abstract 2355: Palbociclib enhances the antitumor activity of taxanes by abrogating cell cycle checkpoints and alleviating hypoxia in squamous cell lung cancer Cancer Research. 77: 2355-2355. DOI: 10.1158/1538-7445.Am2017-2355  0.41
2016 Sung MS, Tan X, Hosselet C, Cinque M, Upeslacis E, Golas J, Wang F, Lu B, Tylaska L, King L, Myers J, Rosfjord E, Lucas J, Gerber H, Loganzo F. Abstract 2113: Caveolae-mediated endocytosis as a novel mechanism of resistance to T-DM1 ADC Cancer Research. 76: 2113-2113. DOI: 10.1158/1538-7445.Am2016-2113  0.356
2016 Damelin MI, Bankovich A, Bernstein J, Lucas J, Chen L, Williams S, Park A, Aguilar J, Ernstoff E, Charati M, Dushin R, Jackson-Fisher A, Aujay M, Lee C, Ramoth H, ... ... Rosfjord E, et al. Abstract 1220: A novel PTK7-targeted antibody-drug conjugate eliminates tumor-initiating cells and induces sustained tumor regressions Cancer Research. 76: 1220-1220. DOI: 10.1158/1538-7445.Am2016-1220  0.392
2015 Shor B, Kahler J, Dougher M, Xu J, Mack M, Rosfjord E, Wang F, Melamud E, Sapra P. Enhanced Anti-Tumor Activity Of an anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26319086 DOI: 10.1158/1078-0432.Ccr-15-1166  0.384
2015 Kan Z, Rosfjord E, Hardwick J, Ding Y, Zheng X, Fernandez J, Shi S, Ozeck M, Wang H, Troche G, Upeslacis E, Jackson-Fisher A, Ching K, Deng S, Tao X, et al. Abstract A2-33: Molecular profiling of patient-derived xenograft models across cancers Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-A2-33  0.36
2015 Sapra P, Shor B, Dougher M, Kahler J, Mack M, Xu J, Lu S, Melamud E, Wang F, Rosfjord E. Abstract 2463: Enhanced anti-tumor activity of an Auristatin-based antibody-drug conjugate in combination with PI3K/mTOR inhibitors or taxanes: Translational implications and mechanistic insights Immunology. 75: 2463-2463. DOI: 10.1158/1538-7445.Am2015-2463  0.308
2015 Rosfjord E, Han X, Leahy D, Upeslacis E, Lucas J, Golas J, Hooper A, Immermann F, Lu B, Myers J, Kan Z, Hardwick J, Powell E, Sapra P, Rejto P, et al. Abstract 1469: Patient derived xenograft (PDX) models: improving predictability of experimental cancer therapies Cancer Research. 75: 1469-1469. DOI: 10.1158/1538-7445.Am2015-1469  0.336
2014 Rosfjord E, Lucas J, Li G, Gerber HP. Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. Biochemical Pharmacology. 91: 135-43. PMID 24950467 DOI: 10.1016/J.Bcp.2014.06.008  0.355
2014 Dann SG, Golas J, Miranda M, Shi C, Wu J, Jin G, Rosfjord E, Upeslacis E, Klippel A. p120 catenin is a key effector of a Ras-PKCɛ oncogenic signaling axis. Oncogene. 33: 1385-94. PMID 23542175 DOI: 10.1038/Onc.2013.91  0.403
2014 Friedman J, Zhong W, Loreth C, Diesl V, Han X, Lucas J, Hooper A, Buklan V, Rosfjord E, Leahy D, Lucas J, Follettie M, Arndt K. Abstract 3487: CA9 expression highly correlates with cancer stem cell markers during passaging of PDX lines Cancer Research. 74: 3487-3487. DOI: 10.1158/1538-7445.Am2014-3487  0.421
2014 Hooper AT, Chang CB, Marquette K, Golas J, Lucas J, Nichols T, Lucas J, Maria G, Rosfjord E, Xavier A, Scott N, Jain S, Cao W, Leal M, Maderna A, et al. Abstract 2669: Targeting the tumor vasculature with antibody drug conjugates Cancer Research. 74: 2669-2669. DOI: 10.1158/1538-7445.Am2014-2669  0.359
2012 Unsal-Kacmaz K, Ragunathan S, Rosfjord E, Dann S, Upeslacis E, Grillo M, Hernandez R, Mack F, Klippel A. The interaction of PKN3 with RhoC promotes malignant growth. Molecular Oncology. 6: 284-98. PMID 22217540 DOI: 10.1016/J.Molonc.2011.12.001  0.409
2012 Dann SG, Golas J, Miranda M, Shi C, Upeslacis E, Rosfjord E, Jin G, Wu J, Klippel A. Abstract 1235: p120ctn is a key effector of Ras-PKC∈-mediated oncogenic signaling Cancer Research. 72: 1235-1235. DOI: 10.1158/1538-7445.Am2012-1235  0.355
2011 Hebbard L, Cecena G, Golas J, Sawada J, Ellies LG, Charbono A, Williams R, Jimenez RE, Wankell M, Arndt KT, DeJoy SQ, Rollins RA, Diesl V, Follettie M, Chen L, ... Rosfjord E, et al. Control of mammary tumor differentiation by SKI-606 (bosutinib). Oncogene. 30: 301-12. PMID 20818417 DOI: 10.1038/Onc.2010.412  0.397
2010 Zhang N, Ayral-Kaloustian S, Niu C, Nguyen T, Upeslacis E, Mansour TS, Ragunathan S, Rosfjord E. 2-Aryl-4,5,6,7-tetrahydro-1,3-benzothiazol-7-ols as a class of antitumor agents selectively active in securin(-/-) cells. Bioorganic & Medicinal Chemistry Letters. 20: 3903-5. PMID 20627558 DOI: 10.1016/J.Bmcl.2010.05.021  0.317
2004 Pei XF, Noble MS, Davoli MA, Rosfjord E, Tilli MT, Furth PA, Russell R, Johnson MD, Dickson RB. Explant-cell culture of primary mammary tumors from MMTV-c-Myc transgenic mice. In Vitro Cellular & Developmental Biology. Animal. 40: 14-21. PMID 15180438 DOI: 10.1290/1543-706X(2004)40<14:Ecopmt>2.0.Co;2  0.359
2004 Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, Hallett WA, Johnson BD, Nilakantan R, Overbeek E, Reich MF, Shen R, Shi X, Tsou HR, Wang YF, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Research. 64: 3958-65. PMID 15173008 DOI: 10.1158/0008-5472.CAN-03-2868  0.312
1996 Lamb K, Rosfjord E, Brigman K, Rizzino A. Binding of transcription factors to widely-separated cis-regulatory elements of the murine FGF-4 gene Molecular Reproduction and Development. 44: 460-471. PMID 8844688 DOI: 10.1002/(Sici)1098-2795(199608)44:4<460::Aid-Mrd5>3.0.Co;2-J  0.636
1996 Scholtz B, Lamb K, Rosfjord E, Kingsley M, Rizzino A. Appearance of nuclear protease activity after embryonal carcinoma cells undergo differentiation Developmental Biology. 173: 420-427. PMID 8606002 DOI: 10.1006/Dbio.1996.0037  0.619
1995 Rosfjord E, Scholtz B, Lewis R, Rizzino A. Phosphorylation and DNA Binding of the Octamer Binding Transcription Factor OCT-3 Biochemical and Biophysical Research Communications. 212: 847-853. PMID 7626120 DOI: 10.1006/Bbrc.1995.2046  0.548
1994 Rizzino A, Rosfjord E. Transcriptional regulation of the murine k-fgf gene Molecular Reproduction and Development. 39: 106-111. PMID 7999355 DOI: 10.1002/Mrd.1080390116  0.638
1994 Rosfjord E, Lamb K, Rizzino A. Cryptic promoter activity within the backbone of a plasmid commonly used to prepare promoter/reporter gene constructs In Vitro Cellular &Amp; Developmental Biology - Animal. 30: 477-481. PMID 7952517 DOI: 10.1007/Bf02631317  0.621
1994 Rosfjord E, Rizzino A. The Octamer Motif Present in the Rex-1 Promoter Binds Oct-1 and Oct-3 Expressed by EC Cells and ES Cells Biochemical and Biophysical Research Communications. 203: 1795-1802. PMID 7945330 DOI: 10.1006/Bbrc.1994.2395  0.628
1992 Ma YG, Rosfjord E, Huebert C, Wilder P, Tiesman J, Kelly D, Rizzino A. Transcriptional regulation of the murine k-FGF gene in embryonic cell lines Developmental Biology. 154: 45-54. PMID 1426633 DOI: 10.1016/0012-1606(92)90046-J  0.625
Show low-probability matches.